The mode of topical immunomodulators in the immunological network of atopic dermatitis

Clinical and Experimental Dermatology

Volumn 30, Issue 2, 2005, Pages 160-164

  Novak, N ^a   Kwiek, B ^a   Bieber, T ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PIMECROLIMUS; STEROID; T LYMPHOCYTE RECEPTOR; TACROLIMUS;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BURNING SENSATION; CELL SURVIVAL; CYTOKINE RELEASE; DENDRITIC CELL; DRUG FORMULATION; DRUG ISOLATION; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; EOSINOPHIL; HUMAN; IMMUNOMODULATION; KERATINOCYTE; LYMPHOCYTE DIFFERENTIATION; MAST CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN INFLAMMATION; SKIN MANIFESTATION; SKIN SENSATION; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ACUTE DISEASE; DENDRITIC CELLS; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTE SUBSETS; TACROLIMUS;

EID: 15044338583     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01709.x     Document Type: Review

References (33)

1. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus, from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46: 228-41.
2. Ruzicka T, Bieber T, Schopf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis, european tacrolimus multicenter atopic dermatitis Study Group. N Engl J Med 1997; 337: 816-21.
3. Reitamo S, Remitz A, Kyllonen H, Saarikko J. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol 2002; 3: 381-8.
4. Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003; 112: 128-39.
5. Hwang ST. Mechanisms of T-cell homing to skin. Adv Dermatol 2001; 17: 211-41.
6. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 2000; 7: 731-48.
7. Shaw KT, Ho AM, Raghavan A et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995; 92: 11205-9.
8. Migita K, Origuchi T, Kawabe Y et al. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. Transplantation 1999; 68: 1018-23.
9. Marone G, De Spadaro G, M et al. Immunopharmacology of human mast cells and basophils. Int J Clin Laboratory Res 1998; 28: 12-22.
10. Sengoku T, Kishi S, Sakuma S et al. FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol 2000; 22: 189-201.
11. Ito F, Toyota N, Sakai H et al. FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. Arch Dermatol Res 1999; 291: 275-83.
12. Trautmann A, Akdis M, Schmid-Grendelmeier P et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001; 108: 839-46.
13. Kaplan A, Matsue H, Shibaki A et al. The effects of cyclosporin A and FK506 on proliferation and IL-8 production of cultured human keratinocytes. J Dermatol Sci 1995; 10: 130-8.
14. Muschen A, Mirmohammadsadegh A, Jarzebska-Deussen B et al. Differential IL-10 receptor gene expression in acute versus chronic atopic eczema. Modulation by immunosuppressive drugs and cytokines in normal cultured keratinocytes. Inflamm Res 1999; 48: 539-43.
15. Karashima T, Hachisuka H, Sasai Y. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. J Dermatol Sci 1996; 12: 246-54.
16. Wakugawa M, Nakamura K, Akatsuka M et al. Interferon-gamma-induced RANTES production by human keratinocytes is enhanced by IL-1beta, TNF-alpha, IL-4 and IL-13 and is inhibited by dexamethasone and tacrolimus. Dermatology 2001; 202; 239-45.
17. Wollenberg A, Wen S, Bieber T. Langerhans cell phenotyping: a new tool for differential diagnosis of inflammatory skin diseases [letter]. Lancet 1995; 34-6: 1626-7.
18. Kerschenlohr K, Decard S, Przybilla B, Wollenberg A. Atopy patch test reactions show a rapid influx of inflammatory dendritic epidermal cells in patients with extrinsic atopic dermatitis and patients with intrinsic atopic dermatitis. J Allergy Clin Immunol 2003; 111: 869-74.
19. Panhans-GroBA, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345-52.
20. Wollenberg A, Sharma S, Von Bubnoff D et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107: 519-25.
21. Wollenberg A, Bieber T. Topical immunomodulatory agents and their targets in inflammatory skin diseases. Transplant Proc 2001; 33: 2212-6.
22. Reich K, Hugo S, Middel P et al. Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis. J Allergy Clin Immunol 2002; 109: 681-7.
23. Reich K, Heine A, Hugo S et al. Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells. J Immunol 2001; 167: 6321-9.
24. Matsue H, Yang C, Matsue K et al. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 2002; 169: 3555-64.
25. Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Invest Med 2001; 49: 442-9.
26. Ponath PD, Qin S, Ringler DJ et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996; 97: 604-12.
27. Wedi B, Raap U, Lewrick H, Kapp A. Delayed eosinophil programmed cell death in vitro, a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997; 100: 536-43.
28. Wollenberg A, Kraft S, Oppel T, Bieber T. Atopic dermatitis: pathogenetic mechanisms. Clin Exp Dermatol 2000; 25: 530-4.
29. Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995; 96: 302-18.
30. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-60.
31. Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol 2000; 105: 782-7.
32. Meurer M, Wozel G. The treatment of atopic dermatitis in adults with topical calcineurin inhibitors. Hautarzt 2003; 54: 424-31.
33. Stander S, Luger TA. Antipruritic effects of pimecrolimus and tacrolimus. Hautarzt 2003; 54: 413-7.